- Home
- CRNX vs ACLX Comparison
CRNX vs ACLX Comparison
Compare CRNX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$47.37
HOLD
Current Price
$69.82
Company Overview
Basic Information| Metric | CRNX | ACLX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CRNX | ACLX |
|---|---|---|
| Price | $47.37 | $69.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $75.78 | ★ $113.75 |
| AVG Volume (30 Days) | ★ 1.3M | 894.8K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,535,000.00 | ★ $35,898,000.00 |
| Revenue This Year | $499.13 | N/A |
| Revenue Next Year | $893.14 | $309.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.74 | N/A |
| 52 Week Low | $24.10 | $47.86 |
| 52 Week High | $57.99 | $94.07 |
Technical Indicators
Market Signals| Indicator | CRNX | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 54.46 |
| Support Level | $50.84 | $66.87 |
| Resistance Level | $50.57 | $71.23 |
| Average True Range (ATR) | 2.27 | 3.12 |
| MACD | -0.95 | 0.38 |
| Stochastic Oscillator | 8.25 | 36.10 |
Price Performance
Historical Comparison CRNX
ACLX
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.